Pfizer, BioNTech Announce Positive Results from Trial of COVID-19 Vaccine in Children Ages 5-11
Pfizer Inc. and BioNTech SE today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 micrograms administered 21 days apart, a smaller dose than the 30 micrograms dose used for people 12 and older. Awesome!
Photo Credit: Aziz Acharki